Growth Strategy: Evidence-Based Reimbursement and Commercialization Strategies for Innovators and Investors
November 3, 2010
In today’s rigorous health care environment new products must present a high profit and value proposition to potential investors and acquirers. Along with this increased level of scrutiny, payers are reviewing comparative effectiveness data and more carefully examining economic data for reimbursements. In this session panelists will discuss:
- Medicare product coverage strategy
- Proper planning for product pricing
- Preparing comparative effectiveness data
- Working with payer expectations
- Data that should be in place for partnering or acquisition deals
Panelists:
- Judith A. Waltz, Partner, Foley & Lardner LLP
- Anita Chawla, Ph.D., Vice President, Analysis Group
- Antoun Nabhan, Director of Corporate Development, Onyx Pharmaceuticals
Related Insights
June 20, 2025
Foley Career Perspectives
Foley Juneteenth Program: Exploring the Hidden History to Further Our Mutual Understanding
In celebration of Juneteenth, Foley & Lardner welcomed Dr. Deirdre Cooper Owens, author and historian, for a firmwide virtual program on…
July 10, 2025
Events
Mandatory Roth Catch-up
Join Foley’s upcoming webinar on mandatory Roth catch-up contributions effective January 1, 2026. Learn how the new rules impact high earners, what guidance exists, and practical tips for plan compliance.
June 20, 2025
Foley Viewpoints
Federal Court Enjoins Former Franchisees and Two Related Entities from Competing Against Franchisor
A federal court recently granted in part and denied in part a franchisor’s motion to enjoin the post-termination activities of its former…